biote Corp
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
BTMD$1.11+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $89,002 | $79,231 |
| Accounts receivable, net | 6,809 | 6,948 |
| Inventory, net | 17,307 | 11,183 |
| Other current assets | 9,225 | 3,816 |
| Total current assets | 122,343 | 101,178 |
| Property and equipment, net | 1,218 | 1,504 |
| Capitalized software, net | 4,973 | 5,073 |
| Operating lease right-of-use assets | 1,877 | 2,052 |
| Deferred tax asset | 24,884 | 1,838 |
| Total assets | $155,295 | $111,645 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $4,155 | $4,112 |
| Accrued expenses | 8,497 | 6,274 |
| Term loan, current | 6,250 | 6,250 |
| Deferred revenue, current | 3,002 | 1,965 |
| Operating lease liabilities, current | 311 | 165 |
| Total current liabilities | 22,215 | 18,766 |
| Term loan, net of current portion | 106,630 | 112,086 |
| Deferred revenue, net of current portion | 1,322 | 926 |
| Operating lease liabilities, net of current portion | 1,680 | 1,927 |
| TRA liability | 18,894 | — |
| Warrant liability | — | 4,104 |
| Earnout liability | 41,100 | 32,110 |
| Total liabilities | 191,841 | 169,919 |
| Commitments and contingencies (See Note 18) | ||
| Stockholders’ Deficit | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding as of December 31, 2023 and December 31, 2022 | — | — |
| Class A common stock, $0.0001 par value, 600,000,000 shares authorized; 35,842,383 and 11,242,887 shares issued, 34,254,883 and 9,655,387 shares outstanding as of December 31, 2023 and December 31, 2022, respectively | 3 | 1 |
| Class V voting stock, $0.0001 par value, 100,000,000 shares authorized; 38,819,066 and 58,565,824 shares issued, 28,819,066 and 48,565,824 shares outstanding as of December 31, 2023 and December 31, 2022, respectively | 3 | 5 |
| Additional paid-in capital | — | — |
| Accumulated deficit | (29,391) | (44,460) |
| Accumulated other comprehensive loss | (12) | (5) |
| biote Corp.’s stockholders’ deficit | (29,397) | (44,459) |
| Noncontrolling interest | (7,149) | (13,815) |
| Total stockholders’ deficit | (36,546) | (58,274) |
| Total liabilities and stockholders’ deficit | $155,295 | $111,645 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.